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Abstract
Background—The development of the Diagnostic and Statistical Manual of Mental Disorders 
5th edition (DSM-5) and ICD-11 has led to reconsideration of diagnostic criteria for posttraumatic 
stress disorder (PTSD). The World Mental Health (WMH) Surveys allow investigation of the 
implications of the changing criteria compared to DSM-IV and ICD-10.
Methods—WMH Surveys in 13 countries asked respondents to enumerate all their lifetime 
traumatic events (TEs) and randomly selected one TE per respondent for PTSD assessment. 
DSMIV and ICD-10 PTSD were assessed for the 23,936 respondents who reported lifetime TEs in 
these surveys with the fully structured Composite International Diagnostic Interview (CIDI). 
DSM-5 and proposed ICD-11 criteria were approximated. Associations of the different criteria 
sets with indicators of clinical severity (distress-impairment, suicidality, comorbid fear-distress 
disorders, PTSD symptom duration) were examined to investigate the implications of using the 
different systems.
Results—A total of 5.6% of respondents met criteria for “broadly defined” PTSD (i.e., full 
criteria in at least one diagnostic system), with prevalence ranging from 3.0% with DSM-5 to 
4.4% with ICD-10. Only one-third of broadly defined cases met criteria in all four systems and 
another one third in only one system (narrowly defined cases). Between-system differences in 
indicators of clinical severity suggest that ICD-10 criteria are least strict and DSM-IV criteria 
most strict. The more striking result, though, is that significantly elevated indicators of clinical 
significance were found even for narrowly defined cases for each of the four diagnostic systems.
Conclusions—These results argue for a broad definition of PTSD defined by any one of the 
different systems to capture all clinically significant cases of PTSD in future studies.
Keywords
Posttraumatic stress disorder; World Mental Health Surveys; epidemiology; nosology; DSM-IV; 
DSM-5; ICD-10; ICD-11
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INTRODUCTION
Diagnostic criteria for posttraumatic stress disorder (PTSD) have changed with each edition 
of the Diagnostic and Statistical Manual of Mental Disorders (DSM), including the recent 
release of DSM-5, reflecting in part debates about the distinctions between normal responses 
to traumatic stressors versus maladaptive reactions[1] and the potential for inappropriate 
medicalization of suffering.[2] The diagnostic criteria for PTSD have also varied across 
editions of the International Classification of Diseases (ICD), with anticipated tightening of 
criteria in the forthcoming 11th edition in order to emphasize the importance of avoiding 
overdiagnosis of PTSD.[3] These changes to the PTSD diagnosis, evident in DSM-5 and 
anticipated in ICD-11, have reinvigorated debate about the appropriate criteria for PTSD and 
the implications of differences in diagnostic criteria across each of the diagnostic 
systems.[4–8]
DSM-IV and ICD-10 criteria for PTSD differ in multiple ways (Appendix, Table A1). First, 
DSM-IV defined the traumatic event (TE) as one that causes threat to the integrity of the 
person or others (A1 criterion), with the reaction of the individual characterized by intense 
fear, helplessness, or horror (A2 criterion),[9] whereas ICD-10 Diagnostic Criteria for 
Research (ICD-10-DCR) refer to the importance of events that precipitate distress in almost 
anyone.[10] Second, although DSM-IV criteria include both avoidance and numbing 
symptoms, ICD-10-DCR includes only the presence of avoidance symptoms. Third, DSM-
IV requires the presence of clinically significant distress or impairment, whereas ICD-10-
DCR does not. Fourth, DSM-IV requires that symptoms continue for at least 1 month, 
whereas ICD-10-DCR emphasizes that symptoms begin within 6 months of the event and 
that some persist, but does not specify a minimum required duration.
Two important changes to the definition of a traumatic stressor and the associated symptoms 
needed to qualify for a PTSD diagnosis have been made in DSM-5[11] (Appendix, Table 
A1). First, based on evidence that the A2 criterion had insufficient clinical utility, the 
requirement of a subjective response of fear, helplessness, or horror to the event was 
eliminated.[4] By eliminating A2, DSM-5 expanded the context of PTSD from exclusively a 
fear-based anxiety disorder to a disorder that also included anhedonic/dysphoric and 
externalizing phenotypes. Second, based on factor analyses of PTSD symptoms,[4] the 
number of clusters of PTSD symptoms required to qualify for a diagnosis was increased 
from 3 to 4, with avoidance and numbing symptoms split into separate clusters and 
expanded to represent avoidance and persistent negative alterations in cognitions and mood. 
The expanded symptoms include persistent negative evaluation of self or others, elevated 
self-blame, a negative emotional state, and reckless or self-destructive behavior.
Anticipated revisions to the PTSD diagnosis in ICD-11[3,12,13] emphasize that the construct 
of PTSD should have both global applicability and clinical utility,[14] reflecting concerns 
about the potential overuse of PTSD in disaster-exposed populations[15] (Appendix, Table 
A1). In keeping with previous recommendations,[16,17] the ICD-11 workgroup has 
recommended including three core symptom clusters (re-experiencing, avoidance of 
traumatic reminders, and hyperarousal) and removing nonspecific symptoms that are also 
found in other conditions (e.g., trouble concentrating, sleep problems). Re-experiencing the 
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TE refers not only to remembering the event, but also to experiencing the event as occurring 
again, as in nightmares and flashbacks. Duration of required symptoms and degree of 
functional impairment are used to differentiate normal reactions to traumatic stressors from 
PTSD, and PTSD is differentiated from complex PTSD that is also characterized by a range 
of other disturbances.[12] By using a narrower and briefer ICD-11 set of symptoms, ICD-11 
aims to better differentiate PTSD from often comorbid conditions.
Several questions about these changes and differences deserve further consideration. First, is 
the DSM-5 suggestion of four symptom clusters supported by investigation of symptom 
structure in a cross-national sample? Second, what is the impact of changes in the diagnostic 
criteria sets on PTSD prevalence cross-nationally? Third, to what extent do the diagnostic 
criteria identify overlapping populations of individuals? Previous evidence suggests that 
prevalence estimates of DSM-IV and ICD-10 PTSD are similar but that the systems identify 
somewhat distinct sets of individuals, although this research is based only on data from one 
country.[18] Fourth, do individuals diagnosed with PTSD using each of the diagnostic 
criteria sets exhibit similar clinical characteristics, including distress, impairment, 
suicidality, and comorbidity? Given that ICD-10 does not require distress and impairment 
for diagnosis, it is likely that ICD-10 cases on average are associated with lower levels of 
such outcomes. Again, prior comparison of DSMIV and ICD-10 PTSD has shown that 
absence of the distress/impairment criterion results in higher PTSD prevalence in 
ICD-10.[18] Fifth, as part of a broader concern with implications of differences among 
systems, is PTSD differentially associated with sociodemographic factors, TE types, and 
prior lifetime history of mental disorder across the systems?
Answering these questions is key to understanding the global impact of changes to the 
diagnostic criteria sets for PTSD. The World Mental Health (WMH) Surveys, a dataset 
comprising thousands of respondents from around the globe, and employing a diagnostic 
instrument with both DSM and ICD criteria for PTSD, provides an important opportunity 
for beginning to do so.
METHODS
SAMPLES
Interviews were administered in 13 countries, including eight classified by the World 
Bank[19] as high income (Belgium, Germany, Italy, Japan, Netherlands, New Zealand, 
Spain, United States), four upper-middle income (São Paulo in Brazil, Bulgaria, Mexico, 
Romania), and one lower-middle income (Colombia). Most surveys were based on 
nationally representative household samples, the exceptions being surveys of all urbanized 
areas in Colombia and Mexico and of specific Metropolitan areas in Brazil (São Paulo) and 
a series of cities in Japan. Response rates ranged from 55.1% (Japan) to 87.7% (Colombia). 
The weighted (by sample size) mean response rate across surveys was 70.3%. Interviews 
were in two parts. Part I, administered to all respondents, assessed core DSM-IV mental 
disorders (n = 67,652 respondents across all 13 surveys). Part II assessed additional 
disorders and correlates. Questions about PTSD were included in Part II, which was 
administered to 100% of Part I respondents who met lifetime criteria for any Part I disorder 
and a probability subsample of other Part I respondents (n = 34,321 across all 13 surveys). 
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Part II respondents were weighted by the inverse of their probability of selection from Part I 
to adjust for differential probabilities of selection. Additional weights adjusted for 
differential within and between household selection and deviations between the sample and 
population demographic–geographic distributions. More details about WMH sample design 
and weighting are presented elsewhere.[20]
MEASURES
Interview Procedures—Interviews were administered face-to-face in respondent homes 
after obtaining informed consent using procedures approved by local Institutional Review 
Boards. The interview schedule was developed in English and translated into other 
languages using a standardized WHO translation, back-translation, and harmonization 
protocol.[21] The full text of the interview schedule is available at 
www.hcp.med.harvard.edu/wmh.
TEs—The WMH interview assessed lifetime exposure to 29 TEs, including seven war-
related (e.g., combatant, civilian in a war zone), five types of physical assault (e.g., beaten 
by a caregiver as a child, mugged), three types of sexual assault (e.g., stalked, attempted 
rape, rape), six involving threats to physical integrity excluding violence (e.g., life-
threatening accidents, natural disasters), five involving threats to loved ones (e.g., life-
threatening illness/injury), and traumatic death of loved one. Two additional open-ended 
questions asked about TEs not included on the list and TEs respondents did not wish to 
describe concretely. Respondents were probed separately about number of lifetime 
occurrences and age at first occurrence of each reported TE type. PTSD was assessed in 
relation to a randomly selected lifetime TE to produce a population-level representative 
sample of TEs.[22] This was done by numbering each occurrence of each reported TE for 
each respondent, then selecting one numbered instance, and then weighting that report by 
the probability of selection of that particular TE for that respondent. This approach produces 
a weighted dataset representative of all lifetime TEs occurring to all respondents. Twenty-
three thousand nine hundred thirty-six Part II respondents (67.1%) reported one or more 
TEs, with 24.6% of those with TEs reporting exactly one and the others reporting a mean of 
6.0 (range 2–160; interquartile range 3–6), for approximately 114,000 TEs. Although PTSD 
was assessed only for one TE per respondent, the sum of weights of these 23,936 
respondents was equal to the total number of TEs rather than the number of respondents.
PTSD—Mental disorders were assessed with the Composite International Diagnostic 
Interview (CIDI),[22] a fully structured interview administered by trained lay interviewers, to 
assess DSM-IV and ICD-10 disorders. The CIDI assessment of PTSD began with questions 
to operationalize the DSM-IV Criterion A2 requirement that the person’s response to the 
focal TE involve intense fear, helplessness, or horror. However, rather than requiring 
responses of this time, all respondents with qualifying TEs were additionally asked about 
DSMIV Criterion B symptoms of persistent re-experiencing, Criterion C symptoms of 
persistent avoidance, and Criterion D symptoms of persistent symptoms of increased 
arousal. Respondents who reported any of these symptoms were then asked about the DSM-
IV Criterion E requirement that symptoms persist more than 1 month and the Criterion F 
requirement that these symptoms cause clinically significant distress or impairment.
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As detailed elsewhere,[23] blinded clinical reappraisal interviews with the Structured Clinical 
Interview for DSM-IV (SCID) were conducted in four WMH countries. CIDI–SCID 
concordance for DSMIV PTSD was moderate[24] (κ = .49; area under the curve (AUC) = .
69). The two components of AUC, sensitivity and specificity, were 38.3 and 99.1, 
respectively, resulting in a likelihood ratio positive (LR+) of 42.0, which is well above the 
threshold of 10 typically used to consider screening scale diagnoses definitive.[25] 
Consistent with the high LR+, the proportion of CIDI cases confirmed by the SCID was 
86.1%, suggesting that the vast majority CIDI cases of DSM-IV PTSD would independently 
be judged to have DSM-IV PTSD by trained clinicians.
ICD-10 criteria were also fully operationalized in the CIDI, as ICD-10 Criteria B–D are a 
subset of the DSM-IV criteria. DSM-5 criteria (11) were approximated by fully 
operationalizing DSM-5 Criteria B (one or more of five symptoms of intrusive recollection), 
C (one or both of two symptoms of avoidance), F (duration of more than 1 month), and G 
(clinically significant distress or impairment), and partially operationalizing Criteria D (two 
or more of four symptoms of negative alterations in cognitions and mood, three of which 
were not assessed in the CIDI) and E (two or more of five symptoms of marked alterations 
in arousal and reactivity, one of which was not assessed in the CIDI). Proposed ICD-11 
diagnostic guidelines (3) were approximated by operationalizing the requirements of (1) 
avoidance of thoughts– memories of the TE or of activities–situations reminiscent of the TE, 
(2) excessive hypervigilance or enhanced startle reactions, and (3) significant impairment in 
functioning, while closely approximating the requirement of (4) re-experiencing the TE in 
the form of either vivid intrusive memories, flashbacks, or nightmares accompanied by fear 
or horror.
Other Mental Disorders—In addition to PTSD, the CIDI assessed five DSM-IV fear 
disorders (panic disorder without agoraphobia, specific phobia, social phobia, agoraphobia 
without history of panic disorder, obsessive compulsive disorder), three distress disorders 
(major depressive disorder/dysthymia, generalized anxiety disorder, bipolar disorders [I-II 
and subthreshold BPD]), three disruptive behavior disorders (oppositional defiant disorder 
[ODD], conduct disorder [CD], intermittent explosive disorder), and two substance disorders 
(alcohol and drug abuse with or without dependence). Age-of-onset of each disorder was 
assessed using special probing techniques shown experimentally to improve recall 
accuracy.[26] DSM-IV organic exclusion rules and diagnostic hierarchy rules were used 
(other than for ODD, which was defined with or without CD, and substance abuse, which 
was defined with or without dependence). As detailed elsewhere,[23] generally good 
concordance was found between these CIDI diagnoses and blinded clinical diagnoses based 
on clinical reappraisal interviews with the SCID.[27]
Other Predictors—Differential predictors of the different types of PTSD were 
investigated. The predictors included gender, age at TE exposure, TE type (war-related, 
other interpersonal violence, intimate/sexual violence, accidents, death of loved one, other 
network TEs, and other TEs), numbers of temporally prior lifetime fear/distress disorders 
(anxiety and mood disorders), and number of temporally prior lifetime behavior/substance 
disorders.
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Outcomes—The following four outcomes are considered here: severe distress or 
impairment associated with symptoms of PTSD, as assessed by CIDI questions requiring 
first lifetime onset of suicidal ideation in conjunction with the focal TE in the subsample of 
respondents with no prior lifetime history of suicidality; and first lifetime onset of any fear 
disorders or any distress disorder in the subsample of respondents with no prior lifetime 
history of those disorders. Suicidality was assessed with the CIDI suicidal behavior 
module.[22]
ANALYSIS METHODS
Multivariate additive associations among PTSD symptoms were examined with exploratory 
factor analysis (EFA) of the tetrachoric correlation matrix between all logically possible 
pairs of dichotomously scored symptoms. The parallel analysis simulation method[28] was 
used to select the number of factors to retain in the analysis, whereas promax rotation was 
used to improve our ability to interpret the solution. Prevalence estimates of PTSD based on 
each of the four diagnostic systems, on any of the four systems (referred to below as broadly 
defined PTSD), and on multisystem profiles were then estimated with cross-tabulations.
Regression analysis was then used to examine the associations of PTSD according to the 
different diagnostic systems with each of the four outcomes. As the cross-tabulations 
showed that the numbers of cases in some of the 15 logically possible multivariate profiles 
of diagnoses across the four systems (i.e., 24–1) were too small to allow completely 
disaggregated comparisons, we made only three comparisons for each of the four diagnostic 
systems for each outcome: (1) between narrow cases within the diagnostic system (i.e., 
cases that met criteria for PTSD according to the criteria of the system but not according to 
the criteria of any of the other three systems) and broadly defined noncases (i.e., respondents 
that did not meet criteria for PTSD according to the criteria of any of the four systems); (2) 
between total cases within the diagnostic system (i.e., cases that met criteria for PTSD 
according to the criteria of the system whether or not they also meet criteria in any of the 
other three systems) and broadly defined non-cases; and (3) between other cases (i.e., cases 
that did meet criteria for PTSD according to the criteria of the system but did meet criteria 
for at least one of the other three systems) and broadly defined non-cases.
The equations to predict comorbid fear and distress disorders predicted lifetime first onset of 
each such disorder in the year of TE exposure in the subsample of respondents without a 
prior lifetime history of the outcome disorder. These equations to predict comorbidity were 
based on a combined person-disorder data array. For example, a separate sample of eligible 
respondents was defined for each of the five fear disorders depending on prior lifetime 
history of that disorder, these five datasets were then combined, and a single logistic 
regression equation was estimated in this combined dataset (with four dummy control 
variables to distinguish among the five disorders) to estimate a single set of predictor 
coefficients constrained to be equal across all five outcomes.
We then used logistic regression to examine differences in the sociodemographic, trauma-
related, and psychopathological predictors of PTSD in the four different types of PTSD. 
This was done by estimating four logistic regression equations, one for PTSD diagnoses in 
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each system, that used information about gender, age at TE exposure, type of TE (using the 
seven-category classification scheme described above with traumatic death of a loved one 
serving as the reference category), and prior (to the age of TE exposure) lifetime history of 
fear/distress and behavior/substance disorders (dummy variables for exactly one and more 
than one disorder of each type) to distinguish between total cases according to the focal 
system and other cases. Logistic regression coefficients and their standard errors were 
exponentiated and are reported here as odds ratios (ORs) with 95% confidence intervals 
(CIs). Statistical significance was consistently evaluated using .05-level two-sided tests. The 
design-based Taylor series method implemented in the SAS software system[29] was used to 
adjust for the weighting and clustering of observations.
RESULTS
EFA
EFA was carried out on the matrix of tetrachoric correlations among the 17 DSM-IV 
Criterion B–D symptoms of PTSD assessed in the WMH surveys. Parallel analysis showed 
that four meaningful factors exist in the data (Table 1). Promax rotation lead to a solution 
that corresponded closely to the DSM-5 symptom dimensions of re-experiencing, avoidance, 
numbing, and arousal.
PREVALENCE
A total of 5.6% of respondents meet criteria for PTSD in at least one of the four systems 
(Table 2). We refer to these cases below as having broadly defined PTSD. The system with 
the highest prevalence (standard error in parentheses) is ICD-10 (4.4% [0.3], including 
79.4% of all broadly defined cases), followed by DSM-IV and ICD-11 (3.3 [0.2] and 3.2% 
[0.2], including 58.4 and 57.4%, respectively, of all broadly defined cases), and the lowest is 
DSM-5 (3.0% [0.2], including 53.5% of all broadly defined cases; (Table 3). One-third of 
broadly defined cases (1.8% of all respondents) meet criteria in all four systems, an 
additional one-third of broadly defined cases in either three (0.9% of all respondents) or two 
(an additional 0.9% of all respondents) systems, and the final one-third of broadly defined 
cases (1.9% of all respondents) in only one of the four systems. The much higher prevalence 
of cases based on ICD-10 than the other systems is reflected in the fact that narrow ICD-10 
PTSD is the second most common profile (22.1% of all broadly defined cases), the most 
common being cases meeting criteria in all four systems, while the other narrowly defined 
types are quite uncommon (1.5–6.3% of all broadly defined cases).
VARIATION IN ADVERSE OUTCOMES ASSOCIATED WITH THE DIFFERENT TYPES OF 
PTSD
The vast majority (95%) of the 44 ORs that compare outcomes among respondents with 
PTSD to out comes among respondents classified as broadly defined noncases are greater 
than 1.0 and statistically significant (89%; Table 4). The same is true of all four ORs 
associated with narrowly defined DSM-IV PTSD, all four of those associated with narrowly 
defined DSM-5 PTSD, three of the four ORs associated with narrowly defined ICD-10 
PTSD, and one of the four ORs associated with narrowly defined ICD-11 PTSD. These 
results suggest that each of the four diagnostic systems detects at least some clinically 
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significant cases that are missed by all the other systems. Narrowly defined DSM-IV cases 
tend to be more severe than DSM-IV cases that also meet criteria for PTSD in any of the 
other systems. The opposite is true for narrowly defined ICD-10 and ICD-11 cases, both of 
which have consistently lower severity scores than total cases. The number of narrowly 
defined DSM-5 cases is so small that comparisons between narrowly defined and total 
DSM-5 cases cannot be made. Total DSM-IV and DSM-5 cases are consistently more 
severe than other cases, while total ICD-10 and ICD-11 cases are for the most part less 
severe than other cases.
DIFFERENTIAL PREDICTORS
The associations of age of TE exposure and gender with PTSD risk do not vary significantly 
across the four diagnostic systems (Table 5). However, there is some variation in the 
differential risk of PTSD across TE types depending on the diagnostic system used to define 
PTSD. The most important source of this variation is that interpersonal violence is 
associated with significantly higher PTSD risk relative to traumatic death of a loved one 
when PTSD is defined using ICD-11 criteria (which is true for 57.4% of respondents with 
broadly defined PTSD) rather than criteria based on any of the other diagnostic systems 
(which is true for the remaining 42.6% of respondents with broadly defined PTSD). There is 
also evidence that traumatic death of a loved one is associated with significantly higher 
PTSD risk relative to a number of other TEs when PTSD is defined using narrowly defined 
DSM-IV criteria rather than other criteria. However, given that only 4.4% of respondents 
with broadly defined PTSD have narrowly defined DSM-IV PTSD, these differences are not 
as important as those associated with ICD-11 PTSD. The associations of prior lifetime 
DSM-IV fear/distress and behavior/substance disorders with PTSD risk do not vary 
significantly across the four diagnostic systems other than for a greater importance of having 
exactly one prior externalizing disorder in the small proportion of cases where PTSD is 
defined using narrowly defined DSM-IV criteria rather than other criteria. Finally, predictors 
of broadly defined PTSD include female gender (OR = 1.8), sexual assault (OR = 2.6), and 
prior history of fear/distress (OR = 2.0–4.3) or behavior/substance (OR = 2.0–4.3) disorders.
DISCUSSION
This analysis has a number of limitations, the most important being that PTSD was assessed 
using fully structured lay-administered interviews rather than semistructured clinical 
interviews, that the interviews were based on retrospective reports about lifetime rather than 
recent TEs, that DSM-5 criteria were incompletely operationalized (in particular the newly 
added DSM-5 symptoms were not assessed), and that the proposed ICD-11 diagnostic 
guidelines are not written as research criteria and needed to be approximated. As a 
consequence, the results reported here are likely imprecise, and possibly biased (e.g., with 
underestimation of DSM-5 PTSD prevalence). Nevertheless, the analysis is valuable insofar 
as these are the first large-scale cross-national data comparing DSM-IV, DSM-5, ICD-10, 
and ICD-11 PTSD.
Five findings are noteworthy. The first is that the EFA reported here mirrors the DSM-5 
approach of distinguishing four PTSD symptom clusters.[11] Although a number of previous 
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analyses have also yielded a four-factor solution,[4,30] there has been debate about whether 
the fourth factor should be limited to numbing or should include nonspecific arousal 
symptoms.[31,32] The current findings are the first based on a large cross-national sample 
and support a model in which the factors are re-experiencing, avoidance, numbing, and 
arousal. However, further work, for example, with confirma-tory factor analyses, is needed 
to address fully ongoing debates in the literature about the structure of PTSD symptoms.[33]
Second, although 5.6% of respondents met criteria for “broadly defined” PTSD (in which 
PTSD criteria for any diagnostic system are met), a similar proportion of these broadly 
defined cases met criteria for DSM-5 (53.5 or 3% of total sample) and ICD-11 (57.4 or 3.2% 
of total sample). These diagnostic systems are likely to have similar clinical utility in terms 
of identifying similar proportions of the population. A larger proportion of respondents with 
broadly defined PTSD met ICD-10 diagnostic criteria, consistent with the more stringent, 
conservative approach to PTSD diagnosis taken by DSM-5 and ICD-11.
Third, the different diagnostic systems detect populations of PTSD that show only partial 
overlap. One-third of broadly defined cases (1.8% of all respondents) meet criteria in all 
four systems, an additional one-third in either three (0.9% of all respondents) or two (an 
additional 0.9% of all respondents) systems, and the final one-third (1.9% of all 
respondents) in only one of the four systems. Narrowly defined ICD-10 PTSD comprises 
22.1% of all broadly defined cases, but other narrowly defined types are quite uncommon 
(1.5–6.3% of all broadly defined cases).
Fourth, while differences in associations with indicators of clinical severity are consistent 
with ICD-10 criteria being least strict and DSM-IV criteria most strict (and as intended, 
ICD-11 PTSD is associated with less comorbidity), the more striking result is that indicators 
of clinical significance are found even for narrowly defined cases across all four diagnostic 
systems. Thus, the use of any one diagnostic system will overlook many individuals who 
suffer from clinically significant symptoms, including distress and impairment.
Fifth, little evidence could be found for significant differences in sociodemographic, trauma-
related, or prior lifetime psychopathological (including both fear/distress and behavioral/
substance disorders) predictors of PTSD across the different systems, indicating that there is 
a similar underlying risk profile for PTSD irrespective of the definition. This general pattern, 
and especially the finding that the associations of prior psychopathology with PTSD are 
indistinguishable across the four diagnostic systems, adds support to the argument above 
that all four definitions are providing information on unique clinically significant cases that 
are omitted from the other systems.
These findings extend previous work comparing different diagnostic criteria sets for 
PTSD,[18,34–37] and are consistent with the argument that refinements to DSMIV aimed at 
removing symptoms that overlap with those of other mood and anxiety disorders, are not 
associated with a major change in prevalence of PTSD, nor with evidence of a change in 
disability, comorbidity, or structural validity.[38–41] Based on these findings, we suggest that 
broadly defined PTSD may be a particularly useful additional construct in future 
epidemiological studies of PTSD.
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APPENDIX
TABLE A1
PTSD criteria in DSM-IV, DSM-5, ICD-10, and ICD-11
Symptoms required
DSM-IV criteria
    A1. Exposure to actual or threatened death, serious injury, or a threat to physical integrity of 
oneself or others
    A2. Response to the event involved fear, helplessness, or horror
    B. Persistent re-experiencing One of five
    C. Persistent avoidance and numbing Three of seven
    D. Persistent hyperarousal Two of five
    E. Duration of at least 1 month
    F. Clinically significant distress/impairment
DSM-5 criteria
    A. Exposure to actual or threatened death, serious injury, or sexual violence
    B. Persistent re-experiencing One of five
    C. Persistent avoidance One of two
    D. Persistent numbing Two of four
    E. Persistent hyperarousal Two of five
    F. Duration of at least 1 month
    G. Clinically significant distress/impairment
ICD-10 criteria
    A. Exposure to a stressful event or situation of exceptionally threatening or catastrophic 
nature likely to cause pervasive distress in almost anyone
    B. Persistent re-experiencing
    C. Avoidance
    D. Either (1) or (2) below:
    1. Inability to recall important aspects of the stressor
    2. Persistent hyperarousal Two of five
    E. Criteria B, C, and D must all be met within 6 months of the stressful event
ICD-11 criteria
    A. Exposure to a stressful event or situation of exceptionally threatening or horrific nature 
likely to cause pervasive distress in almost anyone
    B. Persistent re-experiencing that involves not only remembering the TE, but also 
experiencing it as occurring again
    C. Avoidance
    D. Persistent hyperarousal (i.e., heightened perception of current threat)
    E. Clinically significant functional impairment
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TABLE 1
Rotated (promax) standardized regression coefficients based on EFA of CIDI PTSD symptom questions (n = 
23,936)
a
I II III IV
I. Re-experiencing
Repeated unwanted memories of random event .84 .11 .00 .03
Repeated unpleasant dreams about random event .79 .06 –.02 .05
Flashbacks of random event happening .84 .06 –.07 .05
Get very upset when reminded of random event .87 .00 .10 –.05
Have physical reactions when reminded of random event .59 –.05 .16 .20
II. Avoidance
Try not to think about random event .13 .82 –.05 .10
Purposely stay away from things that remind of random event –.03 .75 .28 .05
III. Numbing
Unable to remember important parts of random event –.01 .48 .46 –.10
Lose interest in things used to enjoy .14 .09 .84 –.11
Feel emotionally distant/cut-off from people .08 .14 .84 –.03
Trouble feeling love/happiness toward others –.06 .12 .87 .08
Feel no reason to plan for the future –.07 .09 .79 .11
IV. Arousal
Trouble falling asleep during random event .32 –.12 .18 .50
More irritable than usual during random event .09 –.17 .37 .55
More trouble concentrating during random event .21 –.20 .50 .39
Much more alert/watchful with no real need –.03 .22 –.14 .94
More easily startled by ordinary noises .08 .11 –.01 .83
a
Principal axis factor analysis of weighted (see the text for a discussion of weighting) tetrachoric correlation matrix of responses to dichotomous 
symptom questions.
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TABLE 2
Prevalence of PTSD according to the criteria of each and any of the four diagnostic systems (n = 23,936)
Total sample Among respondents with broadly defined PTSD
a
Percentage (SE) Percentage (SE)
DSM-IV 3.3 (0.2) 58.4 (2.5)
DSM-5 3.0 (0.2) 53.5 (2.5)
ICD-10 4.4 (0.3) 79.4 (2.2)
ICD-11 3.2 (0.2) 57.4 (2.7)
Any 5.6 (0.3) 100.0 -
n 23,936 1,581
a
Broadly defined PTSD = PTSD according to the criteria of any of the four systems.
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TABLE 3
The cross-classification of PTSD prevalence across the four diagnostic systems (n = 23,936)
Total sample Among respondents with broadly defined PTSD
Percentage (SE) Percentage (SE)
I. Meets criteria in all four systems
    DSM-IV, DSM-5, ICD-10,ICD-11 1.8 (0.2) 33.1 (2.2)
II. Meets criteria in three systems
    DSM-IV, DSM-5, ICD-10 0.4 (0.1) 7.7 (1.2)
    DSM-IV, DSM-5, ICD-11 0.3 (0.1) 5.8 (1.3)
    DSM-IV, ICD-10, ICD-11 0.1 (0.0) 2.6 (0.5)
    DSM-5, ICD-10, ICD-11 0.0 (0.0) 0.8 (0.5)
    Any three systems 0.9 (0.1) 16.8 (1.8)
III. Meets criteria in two systems
    DSM-IV, DSM-5 0.1 (0.0) 0.9 (0.3)
    DSM-IV, ICD-10 0.2 (0.1) 2.8 (0.8)
    DSM-IV, ICD-11 0.1 (0.1) 1.4 (1.1)
    DSM-5, ICD-10 0.2 (0.1) 3.3 (1.0)
    DSM-5, ICD-11 0.0 (0.0) 0.5 (0.3)
    ICD-10, ICD-11 0.4 (0.1) 7.0 (1.2)
    Any two systems 0.9 (0.1) 15.8 (1.8)
IV. Meets criteria in one system
    DSM-IV 0.2 (0.0) 4.4 (0.8)
    DSM-5 0.1 (0.0) 1.5 (0.7)
    ICD-10 1.2 (0.2) 22.1 (2.4)
    ICD-11 0.4 (0.1) 6.3 (1.2)
    Any one system 1.9 (0.2) 34.3 (2.4)
V. Meet criteria in any of the four systems
    Any 5.6 (0.3) 100.00 -
n 23,936 1,581
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